SCHEMBL18293284

SCHEMBL18293284

C[C@@H]1Cc2c(sc(N)c2-c2nc3cc(Br)ccc3s2)CN1C(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MYC P01106 2/20 0.37
PPARA Q07869 2/20 0.36
DYRK1A Q13627 2/20 0.35
ADORA1 P30542 3/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
ABL1 P00519 1/20 0.34
BCR P11274 1/20 0.34
MAP4K4 O95819 1/20 0.33
ACACB O00763 1/20 0.33
MKNK1 Q9BUB5 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
APEX1 P27695 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
TUBB4A P04350 1/20 0.32
TUBB P07437 1/20 0.32
TUBA3C P0DPH7 1/20 0.32
TUBA1B P68363 1/20 0.32
TUBA4A P68366 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18293209 1.00 MYC (0.37) MYCPPARADYRK1AADORA1KDM4E
SCHEMBL30408451 1.00 MYC (0.37) MYCPPARADYRK1AADORA1KDM4E
SCHEMBL30407403 1.00 MYC (0.37) MYCPPARADYRK1AADORA1KDM4E
SCHEMBL20248834 0.90 L3MBTL1 (0.40) MYCDYRK1AADORA1KDM4EMAPT
SCHEMBL30408683 0.90 ILK (0.39) MYCDYRK1AADORA1KDM4EMAPT
SCHEMBL18293350 0.90 ILK (0.39) MYCDYRK1AADORA1KDM4EMAPT
SCHEMBL18285808 0.88 MYC (0.39) MYCPPARADYRK1AADORA1KDM4E
SCHEMBL18285809 0.88 MYC (0.39) MYCPPARADYRK1AADORA1KDM4E
SCHEMBL18293093 0.88 ILK (0.42) MYCDYRK1AADORA1KDM4EMAPT
SCHEMBL30407882 0.88 ILK (0.42) MYCDYRK1AADORA1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2023-05-11 US disclosed
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS INC (US) 2023-05-11 US disclosed
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY OXFORD FINANCE LLC, AS COLLATERAL AGENT 2018-06-14 US disclosed
WO-2016197078-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY SYROS PHARMACEUTICALS, INC. (US) 2016-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162851-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 MYC 1/4885PPARA 1747/4885DYRK1A 3731/4885
US-20230144106-A1 COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY MYC, MYCBP, MYCBP2 MYC 1/4885PPARA 1415/4885DYRK1A 3742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.